busi day earn sever tool co consolid updat
model highlight key takeaway sever report held remark
well new management control cost better ever outlook
lag con differ test
tailwind growth target remain intact underscor insul
buy check box held remark well rev ebitda
beat consensu materi core growth upsid vs better omx
y/i drove outsiz ep beat beat grew y/i
highlight dx given impact routin test core growth
vs impress esp rel core lab dx trend roch
life post best core growth ex-process media
tool co far driven surg demand pcr ddpcr antibodi
buy back stock final bought stock bottom march
-- first materi buy-back ever guidanc core growth outlook vs
prior probabl somewhat conserv assum basic contribut
serolog test serolog test evoli instal base higher
thought vs prior view product capac tests/wk
view despit nice ytd run see much reason back bullish stanc
margin still peer new management instil greater cost disciplin
ever valuat ebitda net still compel even
sub-optim margin sotp-bas pt move
core growth line w/ estimate reflect weak china rev
 widespread lab closur push new instal said core
order flat built backlog
key focu call around guidanc call core revenue
declin vs prior con would surpass worst ever
said outlook actual differ core outlook
either exclud test
tailwind despit fact over-index instrument
vs gov t/academ industri area vs
hold growth momentum highlight insul post anoth
solid core growth vs acceler stack vs
despit strong start somewhat better outlook protein
vs prior held revenue guidanc reflect caution around pot impact
clinic trial delay mix clinic appreci valuat
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
matter much right growth stock insul
rev ebitda reluct chase
pleas see import disclosur inform page report
summari chang
ep ep exclud amort start
ep adjust exclud intang amort start
pleas see import disclosur inform page report
pleas see import disclosur inform page report
bio-rad laboratorieshistor project statement incomedollar million except per share amountshistor net product expens share share analysisgross sg ebitda oper margin incom net growth analysisnet gross sg oper net dilut bio-rad laboratori jefferi llc equiti research
pleas see import disclosur inform page report
corp histor project statement incomedollar million except per share amountshistor net product incom expens share share analysiscorpor gross sg oper margin incom net growth analysisnet gross sg oper incom net dilut jefferi llc equiti research
pleas see import disclosur inform page report
bruker corporationhistor project statement incomedollar million except per share amount fiscal year end decemb histor net product incom expens expens share share analysisgross sg ebitda depreci oper margin incom net growth analysisnet gross sg oper incom net dilut bruker corpor jefferi llc equiti research
pleas see import disclosur inform page report
thermo fisher scientif inc histor project statement incomedollar million except per share amountshistor net product incom expens share share analysisgross sg oper margin incom incom net growth analysisnet incom thermo fisher scientif jefferi llc -rad laboratori
ep exclud amort start
ebitda margin
pt impli adj ev base
ebitda ex ddpcr sartoriu
covid test product pcr reagent
share repurchas
pt impli adj ev base
ebitda ex ddpcr sartoriu
slower demand recoveri elect procedur softer
pt impli adj ev base
ebitda ex ddpcr sartoriu
bio entrench clinic diagnost
scienc franchis offer substanti insul
see substanti hidden valu bio droplet digit
pcr ddpcr franchis abil drive
compound-annual-growth-rate lead sustain organ growth
unlik peer uniqu capabl drive
outsiz eps/fcf growth independ macro
favor develop around ip disput
nwc/fcf improv erp tool central
qxone
pleas see import disclosur inform page report
adjust exclud intang amort start
nopat compound-annual-growth-rate next decad
price impli ev
price impli ev rev
deceler growth cell/gen therapi field
add capit deploy activ
surpris departure/retir ceo toni hunt
price impli ev revenu
pure-play bioprocess consum
manufactur remain public arena
directli leverag secular growth biolog drug
see signific catalyst burgeon late-stag
market enabl sustain superior organ
revenu growth trajectori intermedi
bolt-on acquisit activ expand tam
commcerci vaccin
pleas see import disclosur inform page report
nopat compound-annual-growth-rate next decad
gov t/academ lab re-open fulli function
price target impli ev ebitda
new product uptak faster anticip gov t/
academ recoveri
ebita margin
price multipl ev
organ revenu growth
organ revenu growth
slower anticip gov t/academ recoveri
prolong weak industrial/semi demand
deterior condit nmr market weaker eu
price multipl ev
sever year restructur activ
manag better ever despit
challeng near-term backdrop expect
stock recov return normal
underli end-market trend current valuat
fulli reflect long-term profit margin expans
pleas see import disclosur inform page report
